on VALBIOTIS (EPA:ALVAL)
Valbiotis to Present at 2024 EASD Congress
Valbiotis has been selected to present clinical results from the Phase II/III REVERSE-IT study at the 2024 European Association for the Study of Diabetes (EASD) congress. This event will be held from September 9 to 13 in Madrid, Spain. This recognition follows their presentation at the American Diabetes Association's 84th Scientific Sessions, completing a comprehensive clinical program.
The clinical study, focused on TOTUM•63, demonstrates its efficacy against prediabetes and type 2 diabetes. Valbiotis plans to launch TOTUM•63 in France in the first half of 2025, targeting millions at risk of this chronic disease. Discussions for international marketing are also underway.
The REVERSE-IT study is notable for involving 636 volunteers across 52 centers in seven countries. This marks a first for a non-drug active substance in treating early glycemic disorders.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news